



Evaluation of COVID-19 vaccine effectiveness

INTERIM GUIDANCE

17 MARCH 2021



World Health
Organization



COUNTRY READINESS AND DELIVERY

Evaluation of COVID-19 vaccine effectiveness

INTERIM GUIDANCE

17 MARCH 2021



WHO continues to monitor the situation closely for any changes that may affect this interim guidance. Should any factors change, WHO will issue a further update. Otherwise, this interim guidance will expire 2 years after the date of publication.

© World Health Organization, 2021. Some rights reserved. This work is available under the [CC BY-NC-SA 3.0 IGO](#) licence.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned.

WHO reference number: WHO/2019-nCoV/vaccine_effectiveness/measurement/2021.1

Contents

Acknowledgements	v
Abbreviations	vi
Key messages	vii
1. Introduction	1
1.1 Purpose of this guide and target audience	1
1.2 Epidemiology of COVID-19	2
1.3 COVID-19 vaccine landscape, regulatory status and policy considerations	2
1.4 Suggested criteria to undertake VE evaluations of COVID-19 vaccines	3
2. The role of VE and impact studies for COVID-19 vaccines	5
2.1 The role of VE studies in evaluating COVID-19 vaccines	5
2.2 COVID-19 vaccine effectiveness versus impact	6
3. Outcomes of interest for VE evaluations	8
3.1 COVID-19 deaths	8
3.2 Severe COVID-19 disease	8
3.3 Symptomatic COVID-19 disease	9
3.4 COVID-19 Infection and transmission	10
3.5 Laboratory-confirmed versus syndromic outcomes	10
3.6 Duration of protection	11
4. Assessing COVID-19 vaccination history	13
5. Measuring covariates	15
6. Study designs	18
6.1 Cohort studies	19
6.2 Case-control studies	20
6.3 Test-negative case-control design (TND)	20
6.4 The screening method (case-population method)	21
6.5 Regression discontinuity design (RDD)	22
7. Bias in VE studies of COVID-19 vaccines	23
8. Laboratory considerations	28
8.1 Testing for confirmatory diagnosis	28
8.1.1 Laboratory methods	28
8.1.2 Specimen collection	29
8.1.3 Specimen type	29
8.2 Genomic characterization	29
8.3 Testing for prior infection	30

9. Statistical considerations	31
9.1 Sample size	31
9.1.1 Cohort study	31
9.1.2 Case-control and test-negative design study	32
9.2 Matching	33
9.3 Data collection, management and analyses	33
9.3.1 Data collection and management	33
9.3.2 Characterizing participants	33
9.3.3 Analytic approaches to estimate crude rate/odds ratios	34
9.3.4 Assessing and adjusting for confounders	34
9.3.5 Time since vaccination	34
9.3.6 Final analyses of VE	35
9.3.7 Additional analyses	35
9.3.8 Interpretation and extrapolation of results from VE evaluations	36
9.3.9 Pooling data from multiple VE evaluations	37
10. Platforms to do COVID-19 VE evaluations	38
11. Protection of human subjects and informed consent	41
12. Reporting of results	42
References	43
Annex 1: Examples of vaccine effectiveness protocols	49
Annex 2: Sample size	50
Annex 3: Possible case definitions; inclusion and exclusion criteria	52
Annex 4: Reporting elements	55

Acknowledgements

The development of this document was coordinated by Daniel Feikin and Minal K Patel of the World Health Organization (WHO) Department of Immunization, Vaccines, and Biologicals.

This guidance document was developed with technical input from:

Qian An (United States Centers for Disease Control and Prevention [US CDC])
Isabel Bergeri (Global Influenza Programme, WHO)
Joe Bresee (US CDC)
Ben Cowling (University of Hong Kong)
Natasha Crowcroft (Department of Immunization, Vaccines, and Biologicals, WHO)
Kamal Fahmy (WHO Regional Office for the Eastern Mediterranean)
Siddhivinayak Hirve (Global Influenza Programme, WHO)
Michael Jackson (Kaiser Permanente Washington Health Research Institute)
Sudhir Joshi (WHO Regional Office for South-East Asia)
Gagandeep Kang (Christian Medical College, Vellore, India)
Mark Katz (WHO Regional Office for Europe)
Claudio Lanata (Nutritional Research Institute, Peru)
Maïna L'Azou Jackson (Coalition for Epidemic Preparedness Innovation)
Marc Lipsitch (Harvard University, United States of America)
Jason Mwenda (WHO Regional Office for Africa)
Francisco Nogareda (Consultant to Pan American Health Organization)
Walt Orenstein (Emory University, United States of America)
Justin Ortiz (University of Maryland, United States of America)
Richard Pebody (WHO Regional Office for Europe)
Tamara Pilishvili (US CDC)
Alba Maria Roperio (Pan American Health Organization)
Stephanie Schrag (US CDC)
Peter Smith (London School of Hygiene and Tropical Medicine, United Kingdom of Great Britain and Northern Ireland)
Padmini Srikantiah (Bill & Melinda Gates Foundation)
Lorenzo Subissi (Emerging Diseases and Zoonoses, WHO)
Marta Valenciano (Epiconcept)
David Vaughn (Bill & Melinda Gates Foundation)
Jennifer Verani (US CDC)
Annelies Wilder-Smith (Department of Immunization, Vaccines, and Biologicals, WHO)

Kim Mulholland (Royal Children's Hospital, Melbourne, Australia, and London School of Hygiene and Tropical Medicine, United Kingdom) and Marc-Alain Widdowson (Institute of Tropical Medicine, Antwerp, Belgium) gave a critical review of the document.

Abbreviations

AEFI	adverse events following immunization
aOR	adjusted odds ratio
ARDS	acute respiratory distress syndrome
aRR	adjusted relative risk
ARU	attack rate among the unvaccinated
ARV	attack rate among the vaccinated
CaCo	case-control study
CEM	cohort event monitoring
CEPI	Coalition for Epidemic Preparedness and Innovations
CI	confidence interval
CLIA	chemiluminescence immunoassays
COPD	chronic obstructive pulmonary disease
COVID-19	coronavirus disease 2019
DBP	diastolic blood pressure
ECMO	extracorporeal membrane oxygenation
ELISA	enzyme-linked immunosorbent assays
ERC	ethical review committee
EUA	Emergency Use Authorization
EUL	Emergency Use Listing
Hib	<i>Haemophilus influenzae</i> type b
HMO	health maintenance organization
ICU	intensive care unit
ILI	influenza-like illness
IVIR-AC	Immunization and Vaccine-related Implementation Research Advisory Committee (WHO)
LFI	lateral flow immunoassays
L/MICs	low- and middle-income countries
LRT	lower respiratory tract
NPI	non-pharmaceutical interventions
RDD	regression discontinuity design
rRT-PCR	real-time reverse-transcription polymerase chain reaction

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24029

